GWCM
GSK icon

Godshalk Welsh Capital Management’s GSK GSK Stock Holding History

Godshalk Welsh Capital Management’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-7,320
Closed -$327K – 118
2021
Q1 		$327K Sell
7,320
-7,560
-51% -$343K 0.23% 98
2020
Q4 		$684K Sell
14,880
-3,920
-21% -$180K 0.5% 68
2020
Q3 		$885K Buy
18,800
+12
+0.1% +$601 0.75% 51
2020
Q2 		$958K Sell
18,788
-332
-2% -$17K 0.9% 41
2020
Q1 		$906K Sell
19,120
-320
-2% -$17.1K 0.98% 38
2019
Q4 		$1.14M Buy
19,440
+80
+0.4% +$4.45K 0.94% 42
2019
Q3 		$1.03M Buy
19,360
+80
+0.4% +$4.12K 0.91% 44
2019
Q2 		$964K Buy
19,280
+600
+3% +$30.1K 0.89% 43
2019
Q1 		$976K Buy
18,680
+1,080
+6% +$54K 0.94% 41
2018
Q4 		$841K Buy
17,600
+480
+3% +$23.6K 0.94% 42
2018
Q3 		$860K Buy
17,120
+240
+1% +$12.2K 0.84% 45
2018
Q2 		$851K Hold
16,880
– – 0.89% 44
2018
Q1 		$824K Buy
16,880
+840
+5% +$39.1K 0.89% 45
2017
Q4 		$711K Sell
16,040
-3,240
-17% -$150K 0.72% 56
2017
Q3 		$978K Hold
19,280
– – 0.98% 36
2017
Q2 		$1.04M Sell
19,280
-200
-1% -$10.7K 1.03% 34
2017
Q1 		$1.03M Sell
19,480
-320
-2% -$16.2K 1.01% 37
2016
Q4 		$953K Buy
19,800
+2,520
+15% +$124K 0.98% 34
2016
Q3 		$932K Buy
17,280
+1,040
+6% +$57K 0.96% 36
2016
Q2 		$880K Sell
16,240
-40
-0.2% -$2.11K 0.93% 36
2016
Q1 		$825K Buy
16,280
+160
+1% +$7.97K 0.85% 40
2015
Q4 		$813K Buy
16,120
+2,560
+19% +$130K 0.85% 38
2015
Q3 		$652K Buy
13,560
+800
+6% +$41.6K 0.71% 54
2015
Q2 		$664K Buy
12,760
+1,760
+16% +$99.1K 0.67% 61
2015
Q1 		$635K Buy
11,000
+1,200
+12% +$68.8K 0.65% 62
2014
Q4 		$524K Buy
+9,800
New +$548K 0.48% 73

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCIM
Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Godshalk Welsh Capital Management's GSK Position: Q2 2021 in Review

Godshalk Welsh Capital Management sold out of GSK (GSK) in Q2 2021, closing a stake of 7,320 shares — an estimated $327K sold.

Godshalk Welsh Capital Management first reported a position in GSK in Q4 2014 and held it in 26 quarters. The position peaked at $1.14M in Q4 2019. 799 funds tracked by Wall St. Rank hold GSK as of Q2 2021.

  • Godshalk Welsh Capital Management reported no remaining GSK position as of Q2 2021 after selling out during the quarter.
  • Godshalk Welsh Capital Management sold 7,320 GSK shares in Q2 2021, an estimated $327K.
  • Godshalk Welsh Capital Management first reported a position in GSK in Q4 2014 and held it in 26 quarters.
  • Godshalk Welsh Capital Management's GSK position peaked at $1.14M in Q4 2019.
  • 799 funds tracked by Wall St. Rank held GSK as of Q2 2021.

Based on Godshalk Welsh Capital Management's 13F filing for Q2 2021, filed 9 Aug 2021.